Pfizer Stock News

AstraZeneca raised its annual dividend for the first time in a decade on Thursday, February 10, and forecast higher sales for 2022 as new drugs against cancer, kidney disease, and rare conditions make up for a decline in COVID-19 products. Early data has shown a booster shot of the drugmakers widely-used COVID-19 vaccine and its antibody drug Evusheld both work against the Omicron coronavirus variant. But while the company forecasts sales of Evusheld to grow this year, it expects that will be more than outweighed by a decline in sales of the vaccine amid growing competition. AstraZeneca has started earning a modest profit on the vaccine, which was initially sold at-cost under a deal with its developers at Oxford University. But the company said it would continue to sell it to low-income nations on a non-profit basis. While sales of COVID-19 products are expected to decline by a low-to-mid 20s percentage this year, the London-listed company forecast overall revenues to rise by a high teens percentage, with core earnings up by a mid-to-high 20s percentage.

BREAKING NEWS: Japan health ministry approves Pfizer oral COVID-19 drug ==Kyodo

Canberra, Feb 10 (IANS) Australia has provisionally approved the use of the AstraZeneca vaccine against Covid-19 as a booster shot for people aged 18 years and older. However, in its announcement the Therapeutic Goods Administration (TGA) said that Pfizer and Modernas mRNA vaccines remain the preferred boosters for Australians irrespective of the primary vaccine a [] The post AstraZeneca approved as booster vaccine in Australia appeared first on Buziness Bytes .

The drug, paxlovid, is to be used for the treatment of mild-to-moderate COVID-19 in people 12 and older and who are at high risk of

TOKYO - A Japanese health ministry panel on Thursday approved the use of an oral COVID-19 pill developed by

BREAKING NEWS: Japan health ministry panel approves Pfizer''s oral COVID-19 pill ==Kyodo

The Pet Healthcare Product research report provides a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is reliable, comprehensive and the result of extensive research both primary

The proportion of women who reported side effects after receiving their first, second or third dose of the Pfizer vaccination is almost twice (1.9 times) as much than among men. Read more » The post Israeli Study: Women Report Side Effects of Pfizer Vaccination Twice as Much as Men appeared first on Hamodia . In related news: Canada to Get Iron Dome Radar Technology MKs: Biometric ID Card Program Outrageously Wasteful Qatar Defiant on Hamas Support Israel Withdraws From UNESCO By Email General Gantz, Peacemaker Gantz, in Campaign Videos

AstraZeneca recorded a big jump in revenue on Thursday as it begins to take a profit from its coronavirus vaccine for the first time. The company recorded full-year revenues of $37.4 billion, an increase of 38% from the year before at constant exchange rates. Part of the boost came from $4 billion in sales of its COVID-19 vaccine, developed with the University of Oxford. Despite rising revenue, AstraZeneca reported a pre-tax loss of $265 million due to costs from its purchase of U.S. drug company Alexion Pharmaceuticals and new drug research. The Anglo-Swedish drugmaker said in November it would begin to take a "modest" profit from the COVID-19 shot, which it had been providing "at cost" - around $2 to $3 -following an agreement with Oxford. Other COVID-19 vaccine producers, such as Pfizer and Moderna, have been booking hefty profits on their shots all along. In the three months to September, the company said revenue jumped by about 50%, to a record $9.9 billion. The increase was due to sales of more than $1 billion in COVID-19 vaccines and the inclusion for the first time of some $1.3 billion worth of revenue from its rare disease business unit following the recent acquisition of Alexion.

The U.S. government is planning to roll out COVID-19 shots for children under the age of 5 as soon as Feb. 21, according to a document from the U.S. Centers for Disease Control and Prevention. The U.S. Food and Drug Administration (FDA) is considering authorizing the use of the Pfizer Inc (PFE.N) and BioNTech SE [] The post US Begins Vaccine Rollout For Children Under 5 appeared first on Uzalendo News .

While COVID-19 vaccines remain a controversial issue, what isnt controversial is that they have been extremely profitable for pharmaceutical companies. Thats according to an article published by the Washington Examiner on Tuesday which revealed that drug manufacturer Pfizer managed to generate billions in revenue off of its two-dose vaccine. Big profits The Examiner cited the [] The post Earnings report shows Pfizer took in almost $37 billion from COVID vaccine sales first appeared on Conservative Institute .

Dev of mRNA vaccines should have revolutionised the global Covid response. But weve let Pfizer withhold this essential medical innovation from much of the world, all while ripping off public health systems with an eye-watering mark-up @TimBierley t.co/drvHEfq0gZ

Pfizer has signed a voluntary licensing with UN-backed Medicines Patent Pool (MPP) allowing the latter to grant sub-licences of Paxlovid to qualified generic drugmakers for supplying in 95 LMICs including India.

Claudia Ceron, a Salt Lake County Health Department community health worker and vaccinator, high-fives kindergartner Eddie Purcell after he received a COVID-19 vaccination at Hillsdale Elementary School in West Valley City on Monday, Nov. 8, 2021. | Kristin Murphy, Deseret News Fast-tracked federal approval process gets underway next week Children as young as 6 months old could be getting vaccinated against COVID-19 before the end of February. The first shipment of 23,000 Pfizer vaccine doses that have been scaled down for children 6 months to 4 years old could arrive in Utah as soon as Feb. 21, the Utah Department of Healths immunization director, Rich Lakin said Wednesday. Therea already plans to quickly distribute those doses to local health departments, doctors and pharmacies throughout the state, even though the fast-tracked process for federal approval doesnt get underway until the U.S. Food and Drug Administrations vaccine advisory committee meets Feb. 15. We know that weve got more kids in this state so the more we get vaccinated, the less it spreads among families and in schools and etc., Lakin said.

The CDC has yet to authorize Pfizer''s COVID-19 vaccine for children as young as 6 months